COMPANY
Cognoptix
Cognoptix is currently developing combined optical scanning devices and diagnostic agents based on these discoveries for clinical, commercial and academic research use. From company website Source · Oct 12, 2026
Timeline
- Trial start Phase 1: Aftobetin-HCl and Fluorescence Detection Measured by Sapphire II to Determine the Number and Timing of Administrations source ↗
Clinical trials (lead sponsor) 1
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT02928211 | Aftobetin-HCl and Fluorescence Detection Measured by Sapphire II to Determine the Number and Timing of Administrations | Phase 1 | Unknown status (ClinicalTrials.gov) | 2016-07 | 2018-12 (estimated) |